Qiagen (NYSE: QGEN) reported Q3 EPS of $0.35, versus $0.33 reported last year. Revenue for the quarter came in at $377.9 million, versus $381.07 million reported last year.

• Q3 2018 results exceed targets as QIAGEN on track to achieve 2018 goals:
  • Net sales of $377.9 million +3.8% reported (+6.5% at constant exchange rates, or CER vs. ~6% CER guidance)
  • EPS of $0.26; adjusted EPS $0.35 ($0.36 CER vs. ~$0.33-0.34 CER guidance)
  • Free cash flow for first nine months of 2018 rises 21% to $176.7 million
• Sample to Insight portfolio building momentum:
  • QuantiFERON latent TB test: Maintains solid double-digit CER growth pace, launch of new automation options provide faster workflows for customers
  • QIAstat-Dx: Establishing European footprint in growing market for syndromic testing, on track for U.S. launch in 2019 and menu expansion
  • NeuMoDx: New strategic partnership to address large segment of the Molecular Diagnostics market for integrated PCR
  • NGS: Launch of universal RNA library preparation products and new oncology panels for GeneReader NGS System
• QIAGEN reaffirms 2018 net sales outlook and raises target for adjusted EPS

For earnings history and earnings-related data on Qiagen (QGEN) click here.